Betydningen av komplementsystemet ved gram-negativ sepsis i en human fullblodsmodell
- Prosjektnummer
- SFP902-09
- Ansvarlig person
- Ole-Lars Brekke
- Institusjon
- Nordlandssykehuset HF
- Prosjektkategori
- Flerårig forskningsprosjekt
- Helsekategori
- Inflammatory and immune system
- Forskningsaktivitet
- 6. Treatment Evaluation
Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.
Mol Immunol 2011 Sep;48(15-16):2159-69. Epub 2011 aug 11
PMID: 21839519
Selective inhibition of TNF-alpha or IL-1 beta does not affect E. coli-induced inflammation in human whole blood.
Mol Immunol 2010 May;47(9):1774-82. Epub 2010 mar 23
PMID: 20334922
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis.
Scand J Immunol 2009 Jun;69(6):479-91.
PMID: 19439008
1. Key role of the number of erythrocyte CR1 on the initial erythrocyte binding, phagocytosis and oxidative burst by Escherichia
Abstract utvalgt til oral presentasjon ved 13Th European Congress on Complement in Human Disease. Leiden 21-24 aug. 2011.
2. C1 inhibitor efficiently inhibits Escherichia coli and LPS-induced Tissue factor expression on monocytes and mRNA upregulatio
Abstract utvalgt til oral presentasjon ved 13Th European Congress on Complement in Human Disease. Leiden 21-24 aug. 2011.
3. Challenging pattern recognition cross-talk: A gene profiling perspective of human Gram-negative bacteriaemia.
Abstract ved 13Th European Congress on Complement in Human Disease. Leiden 21-24 aug. 2011.
Effect of anticoagulants and storage temperature on cytokine levels in plasma and serum from healthy humans
Muntlig innlegg ved "Nordic congress in Medical Biochemistry" Oslo, juni 2010.
Effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood
Abstract ved "7th International Innate Immunity Aegean Conference at Rhodes", July 2010
Ingen endring av endotelfunksjon eller inflammasjonsstatus hos pasienter med familiær hyperkolesterolemi behandlet med statiner
Abstract ved Norsk Cardiologisk selskaps årsmøte, Oslo 2010
Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood
Abstract ved "XXIII International complement workshop", New York 1-5 august 2010
Elevated cytokine concentrations in serum compared to plasma samples from healthy humans is not explained by complement
Abstract ved "XXIII International complement workshop", New York 1-5 august 2010
Key role of CD14 in the E. coli- and LPS-induced mRNA down regulation of the C5a receptors CD88 and C5L2
Abstract ved "XXIII International complement workshop", New York 1-5 august 2010
Preanalytisk effekt av antikoagulanter og lagringsbetingelser på cytokinkonsentrasjoner i blodprøver fra friske personer
Abstract ved "Etterutdannelseskurs/høstmøte i medisinsk biokjemi", Thon hotell Nordlys, Bodø 27-29 september 2010
No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treate
J Clin Lipidol. 2010 (4):288-92. PMID: 21122661.
Escherichia coli og Neisseria meningitidis bindes initialt til komplement-reseptor 1 (CR1) på erythrocytter i humant fullblod
Abstract og innlegg ved Helse Nords forskningskonferanse Tromsø mars 2009
No evidence of impaired endothelial function or altered inflammatory state in patients with hypercholesterolemia using statins
Abstract European Atherosclerosis Society 78th Congress
Key role of CR1 in the initial binding of Escherichia coli and Neisseria meningitidis to erythrocytes in human whole blood
Abstract og innlegg ved European meeting on Complement in human Disease, Budapest sept. 2009
Different effects of complement and CD14 in E. coli-induced tissue factor mRNA up-regulation, monocyte expression and functional
Manus submitted sept. 2009 til J of Trombosis and Haemostasis
Escherichia coli og Neisseria meningitidis bindes initialt til komplement-reseptor 1 (CR1) på erythrocytter i humant fullblod
Abstract og innlegg vårmøte i Medisinsk biokjemi, Oslo, april 2009
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport, Helse Nord